Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...